5β-19-norandrostan-3-one | 26729-36-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5β-19-norandrostan-3-one
• 英文别名: (5R,8R,9R,10S,13S,14S)-13-methyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 26729-36-2
• 化学式: C₁₈H₂₈O
• 分子量: 260.42
• InChiKey: QENZOBLYOJSARN-XWIGXIBHSA-N

物化性质

• 沸点：
  364.1±10.0 °C(Predicted)
• 密度：
  1.017±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5β-19-norandrostan-3-one 在 吡啶 、 lithium aluminium tetrahydride 、 potassium tert-butylate 、 氧气 作用下， 生成 3β-Tosyloxymethyl-A-nor-(5α)-oestran-3α-ol
  参考文献：
  名称：

  Alais,J.; Levisalles,J., Bulletin de la Societe Chimique de France, 1971, p. 3731 - 3736

  摘要：

  DOI：
• 作为产物：
  描述：

  Oest-4-en-3-on 在 palladium on activated charcoal 氢气 作用下， 生成 5β-19-norandrostan-3-one
  参考文献：
  名称：

  Alais,J.; Levisalles,J., Bulletin de la Societe Chimique de France, 1971, p. 3731 - 3736

  摘要：

  DOI：

文献信息

• Neuroactive steroids of the androstane and pregnane series
  申请人：CoCensys, Inc.

  公开号：US05925630A1

  公开（公告）日：1999-07-20

  The invention relates to 3.alpha.-hydroxy, 17-(un)substituted derivatives of the androstane series and 3.alpha.-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having the general structural Formula: ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are further defined herein and the dotted lines are single or double bonds. The structure includes androstanes, pregnanes (R.sub.4 =methyl), 19-norandrostanes, and norpregnanes (R.sub.4 =H).

  该发明涉及雄烷系列的3α-羟基，17-(未)取代衍生物和孕烷系列的3α-羟基，21-取代衍生物。这些衍生物能够在GRC上的一个最近确定的位点发挥作用，从而调节大脑的兴奋性，以一种能够缓解压力、焦虑、失眠、情绪障碍（如抑郁症）和癫痫活动的方式。本发明的类固醇衍生物具有以下一般结构式：##STR1##其中R、R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5、R.sub.6、R.sub.7、R.sub.8、R.sub.9和R.sub.10在此进一步定义，虚线表示单键或双键。该结构包括雄烷、孕烷（R.sub.4=methyl）、19-去雄雄烷和去孕烷（R.sub.4=H）。
• Neuroactive 3.alpha.-hydroxy-steroids of the androstane and pregnane series
  申请人：Purdue Pharma Ltd.

  公开号：EP1288220A2

  公开（公告）日：2003-03-05

  The invention relates to a 3α-hydroxy, 17-(un)substituted derivatives of the androstane series and 3α-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at the recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having general structural formula (I), wherein R, R1, R2, R3,R4, R5, R6, R7, R8, R9 and R10 are further defined herein and the dotted lines are single or double bonds. The structure includes androstanes pregnanes (R4 = methyl), 19-norandrostanes, and norpregnanes (R4=H).

  本发明涉及一种 3α-羟基、17-（未）取代的雄甾烷系列衍生物和 3α-羟基、21-取代的孕烷系列衍生物。这些衍生物能够作用于最近确定的 GRC 上的位点，从而调节大脑的兴奋性，从而缓解压力、焦虑、失眠、适合 GRC 活性剂的情绪紊乱（如抑郁症）和癫痫发作活动。本发明的类固醇衍生物是具有通式（I）的衍生物，其中 R、R1、R2、R3、R4、R5、R6、R7、R8、R9 和 R10 在此进一步定义，虚线为单键或双键。该结构包括雄甾烷基孕烷（R4=甲基）、19-去雄甾烷基孕烷和去孕烷（R4=H）。
• 19-nor neuroactive steroids and methods of use thereof
  申请人：Sage Therapeutics, Inc.

  公开号：US10822370B2

  公开（公告）日：2020-11-03

  Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.

  本文提供的是符合式（I）的 3,3-二取代 19-去甲类固醇化合物及其药物组合物。 此类化合物可用于预防和治疗各种中枢神经系统相关疾病，例如，治疗睡眠障碍、情绪障碍、精神分裂症谱系障碍、记忆和/或认知障碍、运动障碍、人格障碍、自闭症谱系障碍、疼痛、脑外伤、血管疾病、药物滥用障碍和/或戒断综合征、耳鸣、癫痫状态。
• NEUROACTIVE STEROIDS OF THE ANDROSTANE AND PREGNANE SERIES
  申请人：Cocensys, Inc.

  公开号：EP0837874A2

  公开（公告）日：1998-04-29
• 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF
  申请人：Sage Therapeutics, Inc.

  公开号：US20190112331A1

  公开（公告）日：2019-04-18

  Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.